Systemic STING agonist therapy drives expression of interferon stimulated genes and downstream production of cytokines in dogs with solid tumors
These data identify tolerated dose levels for a novel, intravenously delivered STING agonist compound that results in on-target effects in systemic and intratumoral immune responses in dogs with solid tumors.
Authors
- Timothy Hart
- Sumita Roy–Ghanta (ORCID: https://orcid.org/0009-0007-9452-1139)
- Jennifer Lenz (ORCID: https://orcid.org/0000-0002-3210-618X)
- Matthew J. Atherton (ORCID: https://orcid.org/0000-0002-9830-3151)
- Hank Schmidt
- Jong W. Yu (ORCID: https://orcid.org/0000-0003-4602-3585)
- June DiBona
Institutions
- GlaxoSmithKline (United States) (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/jitc-2025-013715
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- GlaxoSmithKline
- National Institutes of Health
- National Cancer Institute